Article Text

Download PDFPDF

Risperidone reduced the risk of relapse in outpatient schizophrenia and schizoaffective disorder

Statistics from

OpenUrlCrossRefPubMedWeb of Science

QUESTION: In outpatients with schizophrenia or schizoaffective disorder, is risperidone more effective than haloperidol for reducing the risk of relapse?


Randomised {allocation concealed*}, blinded {patients and clinicians},* controlled trial with follow up to time of treatment discontinuation (Risperidone-USA-79 Study).


40 sites in the US.


397 patients who were 18–65 years of age, had a diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV criteria, had required intensive psychiatric treatment within 24 months before study entry, had received a stable dose of antipsychotic medication for ≥30 days before study entry, had resided at the same address for ≥30 days before study entry, and were judged clinically stable by the principal investigator. Exclusion criteria included another current …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.